A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~33 mi. (Burlington, Vermont, +192 more cities)

University of Vermont Medical Center

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

~33 mi. (Burlington, Vermont, +226 more cities)

University of Vermont Medical Center

EGFR Exon 19 Deletion, +1 more biomarker

Non-Squamous Non-Small Cell Lung Carcinoma

amivantamab, +3 more drugs

chemotherapy, +1 more type

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

~33 mi. (Burlington, Vermont, +523 more cities)

University of Vermont Medical Center

Clear Cell Renal Cell Carcinoma

cabozantinib, +2 more drugs

immunotherapy, +1 more type

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

~33 mi. (Burlington, Vermont, +744 more cities)

University of Vermont and State Agricultural College, +1 more facility

Breast Carcinoma

axillary lymph node dissection, +1 more drug

radiation therapy, +1 more type

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

~33 mi. (Burlington, Vermont, +269 more cities)

University of Vermont Medical Center

ER Positive, +1 more biomarker

Invasive Breast Carcinoma

radiation therapy, +1 more drug

radiation therapy

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

~33 mi. (Burlington, Vermont, +454 more cities)

University of Vermont and State Agricultural College

Classical Hodgkin Lymphoma

brentuximab vedotin, +7 more drugs

chemotherapy, +3 more types

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

~33 mi. (Burlington, Vermont, +173 more cities)

University of Vermont and State Agricultural College

B-Cell Lymphoblastic Leukemia/Lymphoma

asparaginase Erwinia chrysanthemi, +12 more drugs

chemotherapy, +2 more types

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

~33 mi. (Burlington, Vermont, +130 more cities)

University of Vermont Medical Center ( Site 1057)

Bladder Urothelial Carcinoma

BCG solution, +1 more drug

immunotherapy

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~33 mi. (Burlington, Vermont, +172 more cities)

University of Vermont Medical Center

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

~33 mi. (Burlington, Vermont, +664 more cities)

University of Vermont Medical Center, +1 more facility

PD-L1 High Expression (TPS >= 1%), +1 more biomarker

Non-Small Cell Lung Carcinoma

carboplatin, +2 more drugs

chemotherapy, +1 more type

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

~33 mi. (Burlington, Vermont, +174 more cities)

University of Vermont Cancer Center

Non-Small Cell Lung Carcinoma

chemoradiotherapy, +3 more drugs

chemotherapy, +2 more types

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

~33 mi. (Burlington, Vermont, +825 more cities)

University of Vermont Medical Center, +1 more facility

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type